A
Adam Brufsky
Researcher at University of Pittsburgh
Publications - 538
Citations - 33601
Adam Brufsky is an academic researcher from University of Pittsburgh. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 74, co-authored 460 publications receiving 27570 citations. Previous affiliations of Adam Brufsky include MedStar Washington Hospital Center & Kaiser Permanente.
Papers
More filters
Posted ContentDOI
Exome-Capture RNA-Sequencing Of Decade-Old Breast Cancers And Matched Decalcified Bone Metastases Identifies Clinically Actionable Targets
Nolan Priedigkeit,Rebecca J. Watters,Peter C. Lucas,Ahmed Basudan,Rohit Bhargava,William Horne,Jay K. Kolls,Zhou Fang,Margaret Rosenzweig,Adam Brufsky,Kurt R. Weiss,Steffi Oesterreich,Adrian V. Lee +12 more
TL;DR: This study demonstrates the use of ecRNA-seq on decade-old and decalcified specimens and defines expression-based tumor evolution in long-term, estrogen-deprived metastases that may have immediate clinical implications.
Journal ArticleDOI
Whole transcriptome analysis of tumors with discordant oncotype and MammaPrint results in the FLEX trial.
Matei P. Socoteanu,Joyce O'Shaughnessy,Kent Hoskins,Adam Brufsky,C. Graham,Svetislava J. Vukelja,Jamal Misleh,Karen L. Tedesco,Rakhshanda Layeequr Rahman,June Taek Lee,Julian Berrocal,Kamal Sharma,Albert Begas,Jennifer A. Crozier,Ian Grady,Nina D'Abreo,Midas Kuilman,Holly M. Nguyen,Lisa Blumencranz,M. William Audeh +19 more
TL;DR: The genetic basis for discordance is explored by using the FLEX whole transcriptome database to examine differentially expressed genes among patients who received discordant RS and MP results, and highlights the genomic diversity of the RS Intermediate group, as seen with the high number of DEGs.
Proceedings ArticleDOI
P1-08-22: Treatment Patterns and Clinical Outcomes in Elderly Patients with HER2−Positive Metastatic Breast Cancer from the registHER Observational Study.
Peter A. Kaufman,Adam Brufsky,Musa Mayer,Hope S. Rugo,Debu Tripathy,Yood M Ulcickas,Shibao Feng,Li Wang,Melissa Brammer,Denise A. Yardley +9 more
TL;DR: Improved PFS across all age groups and similar trends for OS are suggested and elderly patients with HER2-positive MBC had higher rates of underlying cardiovascular disease than their younger counterparts and received less aggressive treatment, including less first-line trastuzumab.
Journal ArticleDOI
Abstract PD15-05: Assessment of estrogen receptor (ESR1) mRNA expression for prediction of extended aromatase inhibitor benefit in HR-positive breast cancer using NRG Oncology/NSABP B-42
Eleftherios P. Mamounas,Hanna Bandos,Priya Rastogi,Michael Crager,Carolyn Mies,Peter C. Lucas,Charles E. Geyer,Louis Fehrenbacher,Mark Graham,Stephen Chia,Adam Brufsky,Janice M. Walshe,Gamini S. Soori,Shaker R. Dakhil,Soonmyung Paik,Sandra M. Swain,Frederick L. Baehner,Steven Shak,Norman Wolmark +18 more
TL;DR: The B-42 study provided no evidence that ESR1 mRNA as measured by the ER single gene score can inform decisions regarding extended letrozole therapy after 5 years of adjuvant endocrine therapy, and confidence intervals were relatively wide.